Literature DB >> 17509509

Clinical characteristics of exudative age-related macular degeneration in Japanese patients.

Ichiro Maruko1, Tomohiro Iida, Masaaki Saito, Dai Nagayama, Kuniharu Saito.   

Abstract

PURPOSE: To clarify the clinical characteristics of exudative age-related macular degeneration (AMD) in Japanese patients.
DESIGN: Retrospective, observational, consecutive case series.
METHODS: Two hundred and eighty-nine patients with neovascular AMD were examined.
RESULTS: The authors classified the patients into three subtypes of neovascular AMD: polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), and typical AMD. One hundred and fifty-eight patients (54.7%) were diagnosed with PCV and 102 patients (35.3%) with typical AMD. RAP was observed in 13 patients (4.5%). In 16 patients (5.5%), one eye had PCV and the other eye had typical AMD. Most patients with PCV and typical AMD had unilateral disease (81.6% and 94.1%, respectively) with a male preponderance (77.8% and 71.6%, respectively). Nine of 13 patients with RAP were female (69.2%). Patients with RAP were older (mean, 80.3 years for men and 75.3 years for women) than patients with other subtypes. Serous and hemorrhagic pigment epithelial detachment developed in 69 patients (43.7%) with PCV, 22 patients (21.6%) with typical AMD, and nine patients (69.2%) with RAP. In the patients with unilateral disease in each subtype, large drusen in the unaffected eye were seen in 24.0% with PCV, 30.2% with typical AMD, and 77.8% with RAP.
CONCLUSIONS: Neovascular AMD in Japanese patients has different demographic features compared with that in White patients. In Japanese patients, there is a preponderance of PCV, male gender, unilaterality, and absence of drusen in the second eye, with the exception of RAP.

Entities:  

Mesh:

Year:  2007        PMID: 17509509     DOI: 10.1016/j.ajo.2007.03.047

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  186 in total

1.  Association of ARMS2/HTRA1 variants with polypoidal choroidal vasculopathy phenotype in a Korean population.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2011-09-29       Impact factor: 2.447

2.  Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.

Authors:  Akitaka Tsujikawa; Sotaro Ooto; Kenji Yamashiro; Hiroshi Tamura; Atsushi Otani; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

3.  Polymorphisms in the VEGF-A in polypoidal choroidal vasculopathy in a Korean population.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2012-02-04       Impact factor: 2.447

4.  Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.

Authors:  Hae Min Kang; Hyoung Jun Koh; Sung Chul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-21       Impact factor: 3.117

5.  Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.

Authors:  Masaaki Saito; Mariko Kano; Kanako Itagaki; Shigeyuki Ise; Kimihiro Imaizumi; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2015-09-09       Impact factor: 2.447

6.  Polypoidal choroidal vasculopathy with an appearance similar to classic choroidal neovascularisation on fluorescein angiography.

Authors:  Tomohiro Iida
Journal:  Br J Ophthalmol       Date:  2007-09       Impact factor: 4.638

7.  Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy.

Authors:  Kenji Yamashiro; Akitaka Tsujikawa; Akihiro Nishida; Michiko Mandai; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

8.  Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Shunichiro Nakai; Wataru Matsumiya; Akiko Miki; Shigeru Honda; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2019-08-02       Impact factor: 2.447

9.  One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study.

Authors:  San-Ni Chen; Cheng-Kuo Cheng; Ling Yeung; Jiann-Torng Chen; Wei-Chun Chan; Jorn-Hon Liu; Shwu-Jiuan Sheu; Wen-Chuan Wu; Chi-Chun Lai
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

10.  Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Jpn J Ophthalmol       Date:  2016-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.